Friday, November 22

Tag: pharma

Biden Ambushes Pharma Patents – WSJ
10Dec By adminNo Comments
World

Biden Ambushes Pharma Patents – WSJ

While the press frets about Donald Trump establishing the Fourth Reich, President Biden is rewriting laws to arrogate sweeping power for himself. On Thursday the Administration threatened to seize patents of drugs and other innovations, which could be its most economically destructive executive act to date.The Commerce and Health and Human Services Departments are proposing new guidance on “march-in” rights under the 1980 Bayh-Dole Act. The law was meant to encourage cooperation among industry, research institutions and government to bring innovations to market. Mr. Biden’s patent grab will do the opposite.Copyright ©2023 Dow Jones & Company, Inc. All Rights Reserved. 87990cbe856818d5eddac44c7b1cdeb8
Read More
India’s pharma business can reach $130 billion by 2030: Industry experts
28Nov By adminNo Comments
Business

India’s pharma business can reach $130 billion by 2030: Industry experts

NOIDA: India's pharmaceutical business may exceed $130 billion by 2030, supported by expanding market opportunities and heightened demand in the overseas markets, industry experts said on Tuesday.The business stood at over $50 billion for the 2022-23 fiscal, they noted.Chairman of PharmExcil (Pharmaceuticals Export Promotion Council of India) Veeramani S V said the Indian pharmaceutical industry is on a compelling growth trajectory, evidenced by an 8 per cent year-to-date increase in exports and a remarkable 29 per cent surge in October alone."This growth is propelled by expanding market opportunities, heightened demand in the USA, and critical shortages of medicines in the US and Europe. Despite challenges in CIS countries, the global reception of Indian pharmaceuticals remains positive,...
Read More
The Covid Vaccine Windfall Turns for Pfizer and Moderna
19Nov By adminNo Comments
World

The Covid Vaccine Windfall Turns for Pfizer and Moderna

Updated Nov. 19, 2023 3:03 pm ETThe U.S. was in a fit of Covid panic during Thanksgiving week two years ago. The Omicron variant had emerged like a creature from the Black Lagoon. Public-health officials indicated we’d need another updated booster. Share prices in Pfizer and Moderna surged. By month’s end, Pfizer’s stock-market value had surpassed $300 billion, up 50% from the start of the pandemic. Moderna’s shares had soared by more than 1,000% over the same period. In 2022 Pfizer became the first pharmaceutical company to book more than $100 billion in annual sales owing to government purchases of its vaccines and antiviral pill.Copyright ©2023 Dow Jones & Company, Inc. All Rights Reserved. 87990cbe856818d5eddac44c7b1cdeb8
Read More
Viatris to sell India women health care, API businesses for $1.2 billion
2Oct By adminNo Comments
Business

Viatris to sell India women health care, API businesses for $1.2 billion

US-based drugmaker Viatris, previously known as Mylan, is selling its active pharmaceutical ingredients (API) and women’s health care businesses in India for a combined consideration of $1.2 billion (nearly Rs 10,000 crore) as part of a $3.6 billion global divestiture drive to pare debt. The API business is being sold to Secunderabad-based investment firm IQuest Enterprises, while the women’s health care business is going to Spanish firm Insud Pharma. The API business sale includes three manufacturing sites and a research and development (R&D) laboratory in Hyderabad, three manufacturing sites in Visakhapatnam, and third-party API sales, Viatris said in a statement in Pittsburgh, US. The American drugmaker will retain some select R&D capabilities in API...
Read More
Pfizer’s proposed $43 bn takeover of Seagen faces EU investigation
15Jul By adminNo Comments
Business

Pfizer’s proposed $43 bn takeover of Seagen faces EU investigation

By Samuel Stolton Pfizer Inc.’s proposed $43 billion takeover of Seagen Inc. will face an investigation from the European Union’s merger enforcer as the bloc continues to scrutinize large biotechnology deals.      Seagen disclosed in a regulatory filing late Friday that both firms have referred the deal to the European Commission, and the EU executive has accepted jurisdiction for investigating the proposal. The filings say that EU approval is a condition for the deal to close.    In the United States, the Federal Trade Commission will subject the proposed merger to an in-depth antitrust review, as is normal for major deals. The companies said when the takeover was announced that they expected close FTC scrutiny. Pfizer announced in March...
Read More